FNIH MMyeRisk Project: Defining Biomarkers to Stratify Patients at Risk of Developing Multiple Myeloma from MGUS & Smoldering Myeloma
Time: 4:00 pm
day: Conference Day 1
Details:
- Pre-competitive consortia built of varied stakeholders can have an outsize impact
- The FNIH has had success in hematology, specifically in evaluating MRD in ALL, AML, and MM
- Our latest effort, the MMyeRisk project, brings together 8 partners who are working to define biomarkers predictive of progression from MGUS/SMM to Multiple Myeloma
Hematology
